SB 1305, the Agility in Manufacturing Preparedness Act of 2025, would expand the Biomedical Advanced Research and Development Authority’s (BARDA) strategic coordination authority to better support public health and medical preparedness. The bill specifically adds “manufacturing technologies” and “platforms” to the kinds of countermeasure-related initiatives BARDA may pursue, and it directs that BARDA’s strategic coordination may include collaboration with the Manufacturing USA network in biomanufacturing missions.
The bill is aimed at helping develop, demonstrate, and deploy technologies and response capabilities that can strengthen the nation’s ability to prepare for and respond to public health emergencies. In practical terms, it seeks to formalize cooperation between a federal health preparedness agency and federally supported manufacturing institutes so that advanced manufacturing capacity can be leveraged for medical countermeasures and related technologies.
Impact
If enacted, the bill would amend section 319L(c)(4)(F) of the Public Health Service Act, broadening BARDA’s statutory language and explicitly authorizing collaboration with Manufacturing USA institutes. It would not create a new program, but it would expand the scope of permissible strategic initiatives and likely encourage partnerships focused on biomanufacturing, medical supply resilience, and rapid deployment of health technologies. The affected parties would include BARDA, the Manufacturing USA institute network, and entities involved in biomedical manufacturing and emergency preparedness.
Sentiment
Based on the bill text and the limited legislative context provided, the bill appears to have a generally positive, bipartisan-oriented policy framing. It was introduced by Senators Tillis and Coons, suggesting cross-party support, and its stated purpose is to improve preparedness and manufacturing agility rather than to impose restrictions or mandates. There is no recorded committee debate or vote history in the provided materials, so no formal opposition is evident from the available record.
Contention
No specific points of contention are documented in the provided transcripts or vote history. Potential areas of debate, if the bill advances, could include the appropriate scope of BARDA’s collaboration with manufacturing institutes, whether the amendment meaningfully changes federal preparedness capacity, and how such partnerships would be funded or prioritized. However, the available record does not identify any named opponents or disputed provisions.